Growing Investment in R&D to Augment the Global Pharmaceutical Contract Manufacturing Market During the Forecast Period

Pune, India, July, 2023 /press release/- Market Research Future Published a Cooked Research Report on Pharmaceutical Contract Manufacturing Market Research Report.

Market Research Future (MRFR) has published a cooked research report on the “Global Pharmaceutical Contract Manufacturing Market” that contains information from 2018 to 2030. 

Pharmaceuticals Contract Manufacturing Market Highlights

The Global Pharmaceutical Contract Manufacturing Market is accounted to register a CAGR of 6% during the forecast period and is estimated to reach USD 179.4 billion by 2030.

The global pharmaceutical contract manufacturing market refers to the outsourcing of pharmaceutical manufacturing activities to third-party organizations called contract manufacturers. Pharmaceutical companies often partner with contract manufacturing organizations (CMOs) to leverage their specialized facilities, expertise, and resources to produce drugs and pharmaceutical products. The contract manufacturing market in the pharmaceutical industry has been growing rapidly in recent years due to various factors, including cost reduction efforts, focus on core competencies, increased regulatory requirements, and the need for flexible production capacities. Pharmaceutical companies outsource manufacturing to CMOs to streamline their operations, optimize costs, and improve efficiency.

Key Players

MRFR recognizes the following companies as the key players in the Global Pharmaceutical Contract Manufacturing Market — Grifols International, S.A., Catalant, AbbvIE Inc., Boehringer Ingelheim, Lonza AG, Vetter, Patheon Inc., Pharmaceutical Product development

Segment Analysis

The Global Pharmaceutical Contract Manufacturing Market has been segmented based on type.

Based on type, the pharmaceutical contract manufacturing market segmentation includes active pharmaceutical ingredient (API) manufacturing and finished dosage formulation (FDF). The active Pharmaceutical Contract Manufacturing segment held the majority share in 2021, contributing to the pharmaceutical contract manufacturing market revenue. This is primarily owing to the rising government initiatives in the healthcare sector, increasing cancer and age-related diseases, and innovations in biologics across the globe. The finished dosage formulation is the fastest-growing segment in the coming years. For instance, as per the National Institutes of Health (US) statistics published in 2020-2021, the prevalence of degenerative disc disease is typically proportional to age, with 40% of people aged 40 years having degenerative disc disease, rising to 80% among those aged 80 years or over.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Pharmaceuticals Contract Manufacturing Market Research Report

Regional Analysis

The Global Pharmaceutical Contract Manufacturing Market, based on region, has been divided into North America, Europe, Asia-Pacific and the Rest of the World. The North America Pharmaceutical Contract Manufacturing market, accounted for USD 49.4 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the growing incidence of age-related diseases, increasing cancer diseases, biological innovations, and increasing cell and gene therapies across the region.

Europe's Pharmaceutical Contract Manufacturing market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an aging population, and an increase in the incidence of life-threatening disease, cancer incidence, and biologic innovations. Further, the Germany market of pharmaceutical contract manufacturing held the largest market share, and the UK market of pharmaceutical contract manufacturing was the fastest-growing market in the European region.

The Asia-Pacific market of pharmaceutical contract manufacturing is expected to grow at the fastest CAGR from 2022 to 2030. This is due to open pharma companies for manufacturing and developing drugs. Moreover, the China market of pharmaceutical contract manufacturing held the largest market share, and the India market of pharmaceutical contract manufacturing was the fastest-growing market in the Asia-Pacific region.

For instance, the India Pharmaceutical Contract Manufacturing market is the favored destination for medical travelers due to the availability of surgeons, cutting-edge technology, & cost-effective treatments. On the other hand, Singapore is famous for the presence of well-trained doctors, state-of-the-art facilities, and quality care. As per the data cited in the Medical Tourism Index 2021-21 published by Medical Tourism Association in July 2021, Singapore is ranked in 2nd position, Japan at 3rd, India at 10th, South Korea at 14th, and China at 33rd out of the top 46 international healthcare destinations. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2022–2030.

Key Findings of the Study

• The Global Pharmaceutical Contract Manufacturing Market is expected to reach USD 179.4 billion by 2030, at a CAGR of 6% during the forecast period.


• The North America Pharmaceutical Contract Manufacturing market, accounted for USD 49.4 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period.


• Based on type, the pharmaceutical contract manufacturing market segmentation includes active pharmaceutical ingredient (API) manufacturing and finished dosage formulation (FDF). The active Pharmaceutical Contract Manufacturing segment held the majority share in 2021, contributing to the pharmaceutical contract manufacturing market revenue.


• Grifols International, S.A., Catalant, AbbvIE Inc., Boehringer Ingelheim, Lonza AG, Vetter, Patheon Inc., Pharmaceutical Product development